# GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes

> **NCT00252876** · PHASE3 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 2000 (—)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** tesaglitazar

## Key facts

- **NCT ID:** NCT00252876
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-03
- **Primary completion:** —
- **Final completion:** 2007-01
- **Target enrollment:** 2000 (—)
- **Why stopped:** The development program has been terminated
- **Last updated:** 2008-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00252876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00252876, "GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00252876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*